The MMR vaccine is 88% effective when two doses have been given. Around one in two cases are college students.
It's caused by a reactivation of the chickenpox virus, and the skin lesions can last two to four weeks. In people who receive just one shot, the vaccine is less effective.
The Centres for Disease Control (CDC) and Prevention's Advisory Committee on Immunization Practices (ACIP) voted by a slim margin - eight to seven - in favour of GSK's vaccine, which was approved in the United States earlier this month and is a key component of the company's commercial strategy in the next few years with sales expected to exceed £1bn (around $1.4bn). Of these 70 percent had received the vaccination for mumps previously.
"The shingle attack itself is severe and painful to most people, and then there's the possibility that the skin lesions clear up but nerve pain continues", said Dr. Len Horovitz, a pulmonologist at Lenox Hill Hospital in New York City.
Based on these results, the advisory committee voted 8 to 7 to recommend Shingrix for people 50 and older.
That suggests that the immunity people get from the vaccine wears off eventually.
It's not clear at this point whether people who've received Zostavax should come back immediately for Shingrix or wait.
Iran ready to contribute to Iraq's restoration
In an interview on Tuesday before departing for Tehran, Abadi said Iraq would like to work with both the United States and Iran. During Mr Tillerson's visit to Baghdad, PM Haider al-Abadi called the fighters the "hope of Iraq and the region".
An increasing number of outbreaks in recent years prompted the CDC to debate whether a third dose of the vaccine should be recommended, Patel explained.
According to a federal experts panel yesterday (25th October 2017), a third dose of mumps vaccine is recommended when there is an outbreak of the viral disease. That research found Shingrix protected about 90 percent of patients, but Zostavax protected only 50 percent of patients.
Infectious disease specialist Dr. William Schaffner said the effectiveness of the vaccine "begins to wane slowly over 10 or 15 years".
"Shingrix is more expensive and not yet covered by insurance", Swartz said.
"This represents a major advance for people who want to be protected against the disease and its complications", Kathleen Dooling, M.D., M.P.H., a medical officer with the U.S. Centers for Disease Control and Prevention, told the Post.
Shingrix is a non-live herpes zoster vaccine that contains a booster meant to generate a strong and long-lasting immune response. The MMR vaccine protects against measles, mumps, and rubella.